Study | Time period | Number of patients | Number of lesions | Predominant histology of lesions | Dose fractionation | Median follow-up | Local control | Overall survival |
---|---|---|---|---|---|---|---|---|
Folkert et al. 10 | 2005–2012 | 88 | 120 | Leiomyosarcoma (30%), Other/spindle-cell (18%), Hemangiopericytoma/solitary fibrous tumor (16%) | 18–24 Gy/1 fx 24–36 Gy/3–6 fx | 12.3 months | 1-year 87.9% | 1-year 60.6% |
Miller et al. 11 | 2005–2012 | 18 | 36 | Leiomyosarcoma (32%), Chondrosarcoma (17%), Spindle cell (17%) | Median 16 Gy/1 fx (range, 10–25 Gy/1–5 fx) | 15 months | 1-year 50% | 1-year 60% |
Bishop et al. 12 | 2002–2013 | 48 | 66 | Leiomyosarcoma (42%), Epithelioid (14%), MFH/UPS (12%) | BED: < 50 Gy10 (n = 11), 50–59 Gy10 (n = 40), ≥ 60 Gy10 (n = 15) | 19 months | 1-year 81% | 1-year 67% |
Elibe et al. 13 | 2001–2013 | 23 | 53 | Leiomyosarcoma (39%), Ewing’s (13%) | Median 18 Gy/1 fx (range, 10–20 Gy/1 fx) | 14 months | Overall 67% | Median 15.5 months |
This study | 2006–2017 | 44 | 75 | Osteosarcoma (57%), MPNST (12%) | Median 33 Gy/3 fx (range, 18–45 Gy/1–5 fx) | 18.2 months | 1-year 76.4% | 1-year 80.5% |